Skip to content

A randomized controlled trial evaluating the jiangniaosuan formulation as a treatment for hyperuricemic nephropathy at CKD stages 3-4 patients

A randomized controlled trial evaluating the jiangniaosuan formulation as a treatment for hyperuricemic nephropathy at CKD stages 3-4 patients

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ITMCTR
Registry ID
ITMCTR2100005088
Enrollment
Unknown
Registered
2021-07-20
Start date
2021-07-20
Completion date
Unknown
Last updated
2023-02-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

hyperuricemic nephropathy at CKD stages 3-4

Interventions

Sponsors

Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 75 Years

Inclusion criteria

Inclusion criteria: 1. Meet the diagnostic criteria for uric acid nephropathy and TCM syndromes; 2. Age 18-75 years old, with independent behavior ability, no gender limitation; 3. Glomerular filtration rate: 15ml/min<=eGFRCKD-EPI-ASIA<60ml/min; 4. No renal replacement therapy; 5. Sign the informed consent to enter the clinical research.

Exclusion criteria

Exclusion criteria: 1. Those with allergies or allergic constitution to the test drugs and control drugs; 2. Pregnant or lactating female patients; 3. Patients with abnormal liver function (ALT or AST exceeds the upper limit of normal by 2 times or more); 4. Combined with serious primary diseases such as nervous, cardiovascular, digestive, urinary, endocrine and hematopoietic systems, mental patients; 5. Those who are participating in other clinical drug trials; 6. Those who have received similar treatment within 2 weeks before the trial; 7. Patients with uric acid nephropathy with proteinuria (proteinuria>1g/d) or diabetes or hereditary kidney disease.

Design outcomes

Primary

MeasureTime frame
Urinary N-acetyl-ß-D-glucosaminidase;Estimated glomerular filtration rate;Urinary ß2-microglobulin;

Secondary

MeasureTime frame
Chinese medicine clinical symptom score;Urinary microalbumin-creatinine ratio;24-hour urinary protein quantity;Blood urea nitrogen;Serum uric acid;Serum creatinine;24-hour urine uric acid;Urinary retinol binding protein;Kidney B ultrasound;Nitric oxide;

Countries

China

Contacts

Public ContactGao Jiandong

Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine

gaojiandong@hotmail.com+86 18101819551

Outcome results

None listed

Source: ITMCTR (via WHO ICTRP) · Data processed: Feb 4, 2026